Evaluation of Polygenic Risk Score for Epithelial OVarian cancEr Risk Prediction: the PROVE Study

Plain-language summary

This study evaluates the use of a polygenic risk score to predict the risk of epithelial ovarian cancer. It enrolls women newly diagnosed with ovarian or fallopian tube cancer as well as women without this cancer. This non-phase study is currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Catholic University of the Sacred Heart

Intervention

Polygenic Risk Score, Biopsy on normal contralateral ovary, Pharmacogenetic profiles, Full-Field Optical Coherence Tomography (FF-OCT), combined with Dynamic Cell Imaging (Van Gogh System) on detecting ovarian cancer lesions from tissue samples

Start date

6/1/2025

Estimated completion

5/1/2027

Countries

Italy

Related genes

Locations

• Roma, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* For cases: women with a first-time diagnosis of histologically confirmed epithelial ovarian or fallopian tube cancer.
* For Controls women with no concomitant or past OC diagnosis.

Exclusion Criteria:

* For both cases and controls: the presence of concurrent malignancies other from OC.